JP4993649B2 - ホスホネート化合物 - Google Patents

ホスホネート化合物 Download PDF

Info

Publication number
JP4993649B2
JP4993649B2 JP2001541459A JP2001541459A JP4993649B2 JP 4993649 B2 JP4993649 B2 JP 4993649B2 JP 2001541459 A JP2001541459 A JP 2001541459A JP 2001541459 A JP2001541459 A JP 2001541459A JP 4993649 B2 JP4993649 B2 JP 4993649B2
Authority
JP
Japan
Prior art keywords
phosphonate
compound
cidofovir
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001541459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004500352A5 (enExample
JP2004500352A (ja
Inventor
カール ワイ． ホステトラー
ジェイムズ アール． ビードル
ガネッシュ ディー． キニ
Original Assignee
ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア サン ディエゴ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア サン ディエゴ filed Critical ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア サン ディエゴ
Publication of JP2004500352A publication Critical patent/JP2004500352A/ja
Publication of JP2004500352A5 publication Critical patent/JP2004500352A5/ja
Application granted granted Critical
Publication of JP4993649B2 publication Critical patent/JP4993649B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/404—Esters of poly(thio)phosphonic acids containing hydroxy substituents in the hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2001541459A 1999-12-03 2000-12-04 ホスホネート化合物 Expired - Lifetime JP4993649B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16881399P 1999-12-03 1999-12-03
US60/168,813 1999-12-03
US20571900P 2000-05-19 2000-05-19
US60/205,719 2000-05-19
PCT/US2000/033079 WO2001039724A2 (en) 1999-12-03 2000-12-04 Phosphonate compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011153911A Division JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物

Publications (3)

Publication Number Publication Date
JP2004500352A JP2004500352A (ja) 2004-01-08
JP2004500352A5 JP2004500352A5 (enExample) 2011-09-01
JP4993649B2 true JP4993649B2 (ja) 2012-08-08

Family

ID=26864475

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001541459A Expired - Lifetime JP4993649B2 (ja) 1999-12-03 2000-12-04 ホスホネート化合物
JP2011153911A Withdrawn JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物
JP2014002881A Expired - Lifetime JP5963787B2 (ja) 1999-12-03 2014-01-10 ホスホネート化合物
JP2015006124A Expired - Lifetime JP5963894B2 (ja) 1999-12-03 2015-01-15 ホスホネート化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011153911A Withdrawn JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物
JP2014002881A Expired - Lifetime JP5963787B2 (ja) 1999-12-03 2014-01-10 ホスホネート化合物
JP2015006124A Expired - Lifetime JP5963894B2 (ja) 1999-12-03 2015-01-15 ホスホネート化合物

Country Status (18)

Country Link
US (14) US6716825B2 (enExample)
EP (1) EP1233770B1 (enExample)
JP (4) JP4993649B2 (enExample)
KR (1) KR20020073342A (enExample)
CN (1) CN1414854B (enExample)
AT (1) ATE385797T1 (enExample)
AU (3) AU785355B2 (enExample)
BR (1) BR0016058A (enExample)
CA (2) CA2747954C (enExample)
CY (1) CY1107927T1 (enExample)
DE (1) DE60038038T2 (enExample)
DK (2) DK1233770T3 (enExample)
ES (2) ES2300281T3 (enExample)
HK (1) HK1050627B (enExample)
MX (1) MXPA02005490A (enExample)
PT (2) PT1914237E (enExample)
RU (1) RU2258707C2 (enExample)
WO (1) WO2001039724A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014074065A (ja) * 1999-12-03 2014-04-24 Legents Of The Univ Of Calfornia San Diego:The ホスホネート化合物

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
FR2837490B1 (fr) * 2002-03-21 2009-04-17 Univ Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
WO2003075884A1 (en) * 2002-03-06 2003-09-18 Lifizz, Inc. Effervescent compositions comprising bisphosphonates and methods related thereto
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1509537B9 (en) * 2002-04-26 2007-11-14 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
RU2309747C2 (ru) * 2002-09-18 2007-11-10 Михаил Владимирович Кутушов Применение 2-хлорэтилфосфоновой кислоты и ее солей в качестве противоопухолевого средства
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
JP5069463B2 (ja) 2003-04-25 2012-11-07 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス性ホスホネート類似物
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
EP1678322A2 (en) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
WO2005056019A1 (ja) * 2003-12-12 2005-06-23 Astellas Pharma Inc. 悪性黒色腫治療剤
EP1706405B1 (en) 2003-12-22 2009-03-04 Gilead Sciences, Inc. 4'-substituted carbovir- and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2006076015A2 (en) * 2004-04-30 2006-07-20 The Regents Of The University Of California 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof
ES2720618T3 (es) 2004-07-27 2019-07-23 Gilead Sciences Inc Análogos de fosfonato de compuestos de inhibidores de VIH
WO2006055525A2 (en) * 2004-11-15 2006-05-26 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
US8101745B2 (en) 2004-12-16 2012-01-24 The Regents Of The University Of California Lung-targeted drugs
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060219637A1 (en) * 2005-03-29 2006-10-05 Killeen Kevin P Devices, systems and methods for liquid chromatography
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
EP1865967A4 (en) * 2005-04-08 2011-02-09 Chimerix Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
CA2606399A1 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic Use of compounds to enhance processivity of telomerase
US7914810B2 (en) * 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
US8114843B2 (en) 2005-11-18 2012-02-14 The Regents Of The University Of California Photoreactive regulator of protein function and methods of use thereof
EP2012799B1 (en) * 2006-05-03 2016-08-24 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
CN101678122A (zh) * 2007-04-27 2010-03-24 奇默里克斯公司 在核苷给药的受体中降低肾中毒性的方法
JP2011508740A (ja) * 2007-12-27 2011-03-17 エピファニー バイオサイエンシズ， インク． 抗ウイルス化合物
EP3085377A1 (en) 2008-01-25 2016-10-26 Chimerix, Inc. Methods of treating viral infections
NZ590075A (en) 2008-07-08 2012-12-21 Gilead Sciences Inc citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate
US8628812B2 (en) 2008-12-30 2014-01-14 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
EP2270021A1 (en) * 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011005510A2 (en) * 2009-06-22 2011-01-13 Cerapedics, Inc. Peptide conjugates and uses thereof
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
AU2010279678B2 (en) 2009-08-03 2015-09-10 Emergent Biodefense Operations Lansing Llc Composition and methods of treating viral infections and viral induced tumors
EP2483283B1 (en) * 2009-10-02 2015-01-07 Straitmark Holding AG Method for the manufacture of aminohydroxy diphosphonic acids
HUE032860T2 (en) 2010-02-12 2017-11-28 Chimerix Inc A method for treating a virus infection
CN102939291B (zh) 2010-04-14 2016-09-07 加利福尼亚大学董事会 用于病毒感染治疗的具有降低的毒性的膦酸酯
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
AU2015201895B2 (en) * 2010-08-31 2016-11-17 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
BR112013004925B1 (pt) 2010-08-31 2020-09-29 Chimerix, Inc Formas mórficas do éster [[(s)-2-(4-amino-2-oxo-1(2h)-pirimidinil) -1-(hidroximetil)etóxi]metil] mono[3-(hexadecilóxi) propílico] do ácido fosfônico, composições farmacêuticas das mesmas, método para síntese e uso de uma forma mórfica b
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
CN103945869A (zh) * 2011-08-31 2014-07-23 马林克罗特有限公司 使用h-膦酸酯-烯/-炔的氢膦酸酯化反应进行的靶向纳米颗粒的远程组装
ES2734495T3 (es) 2011-12-22 2019-12-10 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
WO2014035945A1 (en) * 2012-08-28 2014-03-06 Glaxosmithkline Llc Pharmaceutical compositions
SI2970346T1 (sl) * 2013-03-15 2018-12-31 The Regents Of The University Of California Aciklični diestri nukleozid fosfonata
IL302520A (en) 2013-11-15 2023-07-01 Chimerix Inc Morphic forms of hexadecyloxypropyl-phosphonate esters
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
PT3194411T (pt) 2014-09-15 2022-06-06 Univ California Análogos de nucleótidos
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
AU2016255725B2 (en) * 2015-04-27 2021-09-23 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
JP6878473B2 (ja) 2016-06-28 2021-05-26 キメリックス インコーポレイテッド ブリンシドフォビルの製剤
RU2628456C1 (ru) * 2016-06-29 2017-08-17 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Новые пиримидиновые ингибиторы репликации аденовируса человека
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
RU2670204C1 (ru) * 2017-12-01 2018-10-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные 2-тиоурацила, обладающие противоаденовирусной активностью
US11447512B2 (en) * 2017-12-21 2022-09-20 Shenzhen Targetrx, Inc. Antiviral nucleoside reverse transcriptase inhibitor
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
US12049474B2 (en) 2019-08-22 2024-07-30 Emory University Nucleoside prodrugs and uses related thereto
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN117285566A (zh) * 2022-06-24 2023-12-26 润佳（苏州）医药科技有限公司 一种膦酸酯类化合物及其医药用途
WO2024020127A1 (en) 2022-07-21 2024-01-25 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194565A (ja) * 1991-07-11 1993-08-03 Toray Ind Inc メチレンジホスホン酸誘導体、その製造方法およびその医薬用途
JPH05339280A (ja) * 1991-04-26 1993-12-21 Japan Tobacco Inc （ｎ−二環置換）アミノメチレンビスフォスフォン酸誘導体
JPH0770159A (ja) * 1993-06-29 1995-03-14 Mitsubishi Chem Corp ホスホナートヌクレオチドエステル誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944530A (en) * 1929-04-08 1934-01-23 Ig Farbenindustrie Ag Phosphoric acid esters
DE2009341C3 (de) * 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
FR2586685B1 (fr) * 1985-09-03 1987-12-11 Protex Manuf Prod Chimiq Procede de preparation de nouveaux agents dispersants cationiques
SU1594953A1 (ru) * 1988-12-30 1991-05-15 Институт Молекулярной Биологии Им.В.А.Энгельгардта Аммонийна соль 9-(4-гидрофосфорил-2-оксабутил)гуанина, обладающа избирательной активностью против вируса простого герпеса
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5879700A (en) * 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
US5618804A (en) 1992-07-10 1997-04-08 Toray Industries, Inc. Methanediphosphonic acid derivative, process for production thereof and use for pharmaceuticals
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
WO1998026749A1 (en) * 1996-12-19 1998-06-25 Kao Corporation Coating composition for teeth
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
IL134619A0 (en) * 1997-08-18 2001-04-30 Univ Kingston Phosphono-carboxylate compounds for treating amyloidosis
FR2781228B1 (fr) * 1998-07-16 2000-09-29 Pf Medicament Phosphonates insatures derives d'indole
US6716825B2 (en) * 1999-12-03 2004-04-06 The Regents Of The University Of California Phosphonate compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05339280A (ja) * 1991-04-26 1993-12-21 Japan Tobacco Inc （ｎ−二環置換）アミノメチレンビスフォスフォン酸誘導体
JPH05194565A (ja) * 1991-07-11 1993-08-03 Toray Ind Inc メチレンジホスホン酸誘導体、その製造方法およびその医薬用途
JPH0770159A (ja) * 1993-06-29 1995-03-14 Mitsubishi Chem Corp ホスホナートヌクレオチドエステル誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014074065A (ja) * 1999-12-03 2014-04-24 Legents Of The Univ Of Calfornia San Diego:The ホスホネート化合物
JP2015078230A (ja) * 1999-12-03 2015-04-23 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア サンディエゴ ホスホネート化合物

Also Published As

Publication number Publication date
US10071110B2 (en) 2018-09-11
HK1050627A1 (en) 2003-07-04
US8008308B2 (en) 2011-08-30
US7790703B2 (en) 2010-09-07
JP5963787B2 (ja) 2016-08-03
US6716825B2 (en) 2004-04-06
ATE385797T1 (de) 2008-03-15
CN1414854B (zh) 2015-08-19
EP1233770A2 (en) 2002-08-28
WO2001039724A3 (en) 2001-10-18
US20130045950A1 (en) 2013-02-21
AU1949701A (en) 2001-06-12
US20040127735A1 (en) 2004-07-01
MXPA02005490A (es) 2004-09-10
DK1914237T3 (da) 2014-09-15
EP1233770A4 (en) 2003-04-16
DE60038038D1 (en) 2008-03-27
AU2010257309B2 (en) 2014-04-10
US20160067268A1 (en) 2016-03-10
US7687480B2 (en) 2010-03-30
US20040019232A1 (en) 2004-01-29
JP2014074065A (ja) 2014-04-24
ES2300281T3 (es) 2008-06-16
CA2747954C (en) 2014-02-25
US20070161602A1 (en) 2007-07-12
CA2393410A1 (en) 2001-06-07
ES2498046T3 (es) 2014-09-24
HK1050627B (en) 2008-12-24
US20100173870A1 (en) 2010-07-08
US8710030B2 (en) 2014-04-29
JP2011246475A (ja) 2011-12-08
AU785355B2 (en) 2007-02-01
AU2006252074A1 (en) 2007-01-18
US20150051174A1 (en) 2015-02-19
US7034014B2 (en) 2006-04-25
US8309565B2 (en) 2012-11-13
JP2015078230A (ja) 2015-04-23
US9206208B2 (en) 2015-12-08
US20170239279A1 (en) 2017-08-24
CN1414854A (zh) 2003-04-30
PT1914237E (pt) 2014-09-09
AU2006252074B2 (en) 2010-09-30
CA2393410C (en) 2011-10-11
US20060281706A1 (en) 2006-12-14
JP5963894B2 (ja) 2016-08-03
RU2258707C2 (ru) 2005-08-20
EP1233770B1 (en) 2008-02-13
CA2747954A1 (en) 2001-06-07
AU2010257309A1 (en) 2011-01-13
US7094772B2 (en) 2006-08-22
DK1233770T3 (da) 2008-06-16
BR0016058A (pt) 2003-07-15
US20050182019A1 (en) 2005-08-18
US20140045794A1 (en) 2014-02-13
US20080103115A1 (en) 2008-05-01
US7098197B2 (en) 2006-08-29
JP2004500352A (ja) 2004-01-08
CY1107927T1 (el) 2013-09-04
KR20020073342A (ko) 2002-09-23
US9649321B2 (en) 2017-05-16
US8889658B2 (en) 2014-11-18
US20120058975A1 (en) 2012-03-08
US20050176673A1 (en) 2005-08-11
WO2001039724A2 (en) 2001-06-07
DE60038038T2 (de) 2009-02-12
PT1233770E (pt) 2008-04-24
US7452898B2 (en) 2008-11-18

Similar Documents

Publication Publication Date Title
JP4993649B2 (ja) ホスホネート化合物
EP1914237B1 (en) Phosphonate ester antiviral compounds
HK1114858A (en) Phosphonate ester antiviral compounds
HK1114858B (en) Phosphonate ester antiviral compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110704

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110712

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120502

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120507

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150518

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4993649

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term